Boston Scientific Corporation (NYSE:BSX) dropped by -0.11 or -0.03 points during the last session to $23 per share. One of the highlights of the day was the net money flow figure, which stood at $2.71 million even as the stock accepted $12.72 million in upticks but rejected $10.01 million in downticks. The up/down ratio for the last observation was a 1.27. The 1-week percentage change for the stock price is registered at 0.86%.A block transaction occurred with $2.08 million in upticks and $0.88 million in downticks while the up/down ratio was calculated to be 2.37. The stock witnessed a net inflow of $1.2 million at the end of the block trade.
Currently the company Insiders own 1.31% of Boston Scientific Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -20.95% . Institutional Investors own 93.31% of Boston Scientific Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -21.18%. On the companys insider trading activities,The officer (EVP, GC & Chief Admin Officer) of Boston Scientific Corp, Pratt Timothy A. sold 24,229 shares at $22.66 on June 1, 2016. The Insider selling transaction had a total value worth of $549,029. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Boston Scientific Corporation (NYSE:BSX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.07 points or 0.3% at $22.95 with 8,227,969 shares getting traded. Post opening the session at $22.96, the shares hit an intraday low of $22.9 and an intraday high of $23.15 and the price was in this range throughout the day. The company has a market cap of $31,140 million and the number of outstanding shares have been calculated to be 1,356,866,900 shares. The 52-week high of Boston Scientific Corporation (NYSE:BSX) is $23.35 and the 52-week low is $14.1801.
Many analysts have stated their opinion on the company shares. Guggenheim Securities initiates coverage on Boston Scientific Corporation (NYSE:BSX). The shares have now been rated Buy by the stock experts at the ratings house. The rating by the firm was issued on June 9, 2016.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.